The expression of the GPX1 gene was associated with increased drug resistance in various cell lines, including SR16157 (for treating breast cancer), fulvestrant (for treating for breast cancer), and bisacodyl active ingredient (for treating glioblastoma). This evidence concerns the gene GPX1 and breast carcinoma.